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Protein kinase C has long been thought to mediate DAG signaling at the synapse. Recently PKC has
been supplanted by members of the Unc13 family as the predominant effectors of DAG signaling.
Thanks to a study by Wierda and colleagues in this issue of Neuron, PKC returns to reclaim part of
the kingdom: both pathways must be active to activate presynaptic potentiation.Synaptic strength can be turned up by
activating G protein-coupled recep-
tors. One of the key outputs of these
G protein pathways is the activation
of phospholipase C, which cleaves
PIP2 to generate diacylglycerol (DAG).
The standard bearer for diacylglycerol
function in the synapse has long been
protein kinase C (PKC). In 2002 PKC
was overthrown and disgraced by
Munc13, the young pretender for the
throne. In this issue of Neuron, studies
from Matthijs Verhage’s laboratory
(Wierda et al., 2007) restore PKC as
coregent with Munc13; in fact, their
data indicate that these proteins con-
verge on the machinery for synaptic
vesicle release in a collaborative and
mutually dependent manner.
Phorbol esters act as stable analogs
of the endogenous lipid DAG. When
applied to neuronal brain slices,
phorbol esters mimicked long-term
potentiation protocols, suggesting
that modulation of synaptic function
required the action of DAG (Malenka
et al., 1986). What are the endogenous
targets of DAG in the brain? It was
known that phorbol esters bound
tightly to the kinase PKC (Kikkawa
et al., 1984). Subsequent studies iden-
tified the so-called C1 domain as the
phorbol ester binding region in PKC
(Ono et al., 1989). It was proposed
that phorbol esters mediated synaptic
potentiation by activating PKC at the
synapse. Pharmacological disruptions
of PKC confirmed this view (Majewski
et al., 1997). Specifically, inhibitors of
PKC, such as bisindolylmaleimide
(BIS), eliminated the phorbol esters-
dependent potentiation. It was be-
lieved that PKC was in fact a uniquetarget of phorbol esters; thus, it was
believed that phorbol ester-mediated
synaptic potentiation occurred solely
through the activation of PKC. This
view dominated for 10 years.
However, the usurper was already
on the scene. The unc-13 gene was
originally identified in the nematode
C. elegans based on the uncoordi-
nated phenotype of mutant animals.
The protein contained a C1 domain
that bound phorbol esters with an
affinity equal to that of PKC (Ahmed
et al., 1992; Maruyama and Brenner,
1991). Unc13 family members are
found in all organisms with nervous
systems. Importantly, it was shown
that disruption of the C1 domain
of Unc13 proteins could prevent or
greatly diminish phorbol ester-
stimulated potentiation in both
C. elegans and mice (Betz et al.,
1998; Lackner et al., 1999). Finally, in
a groundbreaking study, Rhee et al.
(2002) showed that Munc13 was itself
the sole target of phorbol ester action
for synaptic potentiation. A knockin
mutation of Munc13 that did not bind
phorbol esters exhibited normal base-
line synaptic activity, but lacked
potentiation by phorbol esters. Per-
haps PKC was not the relevant target
of DAG after all.
Wierda et al. have now restored PKC
as an essential target of phorbol esters
at the synapse. First, they confirm that
the PKC inhibitors completely block
augmentation. However, pretreatment
with phorbol esters (or by high-
frequency stimulation) 2 min before a
second stimulation with phorbol
esters makes cells immune to PKC
inhibitors. This result was previouslyNeuron 5observed by Rhee et al., and these au-
thors concluded that the late target of
phorbol esters was Munc13. How
could these results be reconciled?
Surely, both cannot be right.
In an elegant series of experiments,
Wierda et al. show that both pathways,
Munc13 and PKC, cooperate to poten-
tiate transmission. A downstream
target of PKC is a syntaxin binding pro-
tein known as Munc18. The authors
expressed a Munc18 without the con-
served PKC phosphorylation sites in
hippocampal cultures lacking the en-
dogenous Munc18 gene. Basal synap-
tic activity was normal, but the neurons
lacked synaptic potentiation when
phorbol esters were added, similar to
the result with Munc13 mutants lack-
ing phorbol ester binding—and in
seeming contradiction. Wierda et al.
argue that DAG activates PKC, which
opens a window during which a sec-
ond DAG signal can then act on
Munc13—a coincidence detector for
two potentiation signals coming in
close succession (Figure 1). The PKC-
inert Munc18 blocks all synaptic po-
tentiation, and activation of Munc13
by phorbol esters is ineffective. By
contrast, a phosphomimetic Munc18
permanently opens the window, and
is therefore resistant to the block by
the PKC inhibitor BIS. This model rec-
onciles the apparently incompatible
observations that both Munc13 and
PKC are absolutely required for poten-
tiation.
Mechanistically, this model is still
in its infancy. In the simplest version,
phosphorylated Munc18 could
interact with Munc13, and the com-
plex would potentiate the synapse.4, April 19, 2007 ª2007 Elsevier Inc. 179
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DAG activation of PKC has a long-acting effect by phosphorylating Munc18. DAG activation of
Munc13 is short-acting. Together, phosphoMunc18 and Munc13 can stimulate the probability
of vesicle fusion (right). The interaction of Munc18 and Munc13 shown is functional and is not
known to be direct.However, two pieces of data argue
that Munc18 does not act directly on
Munc13. Phorbol ester-dependent
Munc13 relocalization to the plasma
membrane still occurs in PKC-inert
Munc18, arguing that the pathways
intercept downstream of Munc13—
perhaps at the level of syntaxin, a mol-
ecule that binds to both Munc13 and
Munc18. Moreover, biochemical stud-
ies of C. elegans homologs indicate
that these proteins have an antagonis-
tic relationship; that is, UNC-13 dis-
places UNC-18 from syntaxin (Sassa
et al., 1999).
There are also published results that
contradict these results. First, in con-
trast to Stevens and Sullivan (1998)
but in agreement with Basu et al.
(2007), the authors observe that phor-
bol ester application does not increase
the size of the ready-releasable vesicle
pool (RRP). Rather, PKC phosphoryla-
tion of Munc18 increases the efficacy
of synaptic vesicle release. This is
true of both calcium-independent
priming mechanisms (as assayed
by subthreshold sucrose stimulation)
and calcium-dependent mechanisms
(as measured during electrical stimula-180 Neuron 54, April 19, 2007 ª2007 Elstion). Second, studies in C. elegans
suggest that DAG activation of PKC
and UNC-13 affect neurotransmission
independently and may even act on
separate synaptic processes (dense
core vesicle and synaptic vesicle exo-
cytosis, respectively) (Sieburth et al.,
2007). These issues will need to be re-
solved in future studies.
Is this the whole story? Well, as with
everything, wrinkles come up. First,
the PKC-inert Munc18 is completely
resistant to phorbol ester application,
suggesting that all PKC function acts
through Munc18. By contrast, the
phosphomimetic Munc18 is only par-
tially resistant to the effects of BIS,
suggesting that PKC has other targets
in addition to Munc18. Previous stud-
ies have implicated different targets,
such as voltage-gated channels and
other presynaptic proteins, as poten-
tial agents of PKC function at the syn-
apse. Second, DAG may have addi-
tional targets in augmentation. For
example, PKD contains C1 domains,
is expressed in neurons, and has
movement defects when knocked out
in C. elegans (Feng et al., 2006). Un-
doubtedly, the usurpers will haveevier Inc.more punches to throw. Nevertheless,
Wierda et al. have proposed a very ap-
pealing model for reconciling the roles
of PKC and Munc13 in potentiation.
And it’s good to have the king back.
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